Guest Reviews on New Drug Targets in Age-Related Disorders

Part II
1. Auflage 2021
ISBN: 978-3-030-55035-6
Verlag: Springer International Publishing
Format: PDF
Kopierschutz: 1 - PDF Watermark

E-Book, Englisch, 272 Seiten, eBook

Reihe: Proteomics, Metabolomics, Interactomics and Systems Biology

Aging is an inevitable part of life, and is becoming a worldwide social, economic and health problem due to the fact that an increasing proportion of individuals in the advanced age category have a higher probability of developing age-related disorders. New therapeutic approaches are still in need to decrease or slow the effects of such diseases in this aging society. Advances in ‘omic technologies such as genomics, transcriptomics, proteomics and metabolomics have significantly advanced our understanding of diseases in multiple medical areas. It is hoped that emerging hits from these analyses might be prioritized for further screening as potential novel drug targets for increasing the human healthspan in line with the lifespan, which will in turn lead to new therapeutic strategies and drug development projects by the pharmaceutical industry. This new book presents a series of reviews describing studies which have resulted in the identification of potential new drug targets for age-related disorders. Much of this information has come from ‘omic comparisons of healthy and disease states or from testing the effects of potential new therapeutic approaches. Each chapter will be presented in the context of specific chronic diseases or different therapeutic strategies, providing important information on disease mechanisms related to the aging process. This book will be of interest to researchers in the areas of aging and chronic disease, as well as clinical scientists, physicians, and major drug companies. With contributors from Australia, Brazil, Canada, France, Germany, India, Iran, Iraq, South Africa, South Korea, Thailand, Ukraine, United Kingdom, United States of America, Uruguay and Vietnam, this is a timely follow up to Guest’s previous book  Reviews on New Drug Targets in Age-Related Disorders.

Zielgruppe

Professional/practitioner

Autoren/Hrsg.

Guest, Paul C.

Inhaltsverzeichnis

New Therapeutic Approaches and Biomarkers for Increased Healthspan.- Targeting Cancer Metabolism and Current Anti-Cancer Drugs.- A Review of Monoclonal Antibody-based Treatments in Non-small Cell Lung Cancer.- Parkinson’s Disease and Impairment in Mitochondrial Metabolism: A Pathognomic Signature.- Targeted Treatment of Age-related Fibromyalgia with Supplemental Coenzyme Q10.- Immunoregulatory Effects of Tolerogenic Probiotics in Multiple Sclerosis.- Multifaceted Roles of Long Non-coding RNAs in Head and Neck Cancer.- A Systematic Review on the Genotoxic Effects of Selective Serotonin Reuptake Inhibitors.- Towards a New Era for the Management of Circulating Tumor Cells.- Telomerase: A target for Therapeutic Effects of Curcumin in Cancer.- Aspirin as a Potential Geroprotector: Experimental Data and Clinical Evidence.- Targeting Stem Cells in Chronic Inflammatory Diseases.- Therapeutic Strategies and Nano-drug Delivery Applications in Management of Aging Alzheimer's Disease.- Psychometric Evaluation of Stress in 17,414 Critical Care Unit Nurses: Effects of Age, Gender and Working Conditions.- Targeting Age-related Neurodegenerative Diseases by AAV Mediated Gene Therapy.- Is Adipose Tissue the Fountain of Youth? The impact of Adipose Atem Cell Aging on Metabolic Homeostasis, Longevity and Cell-Based Therapies.- Proteomics for Target Identification in Psychiatric and Neurodegenerative Disorders.- Index.

Über Autor(innen)

Dr. Paul C. Guest , Ph.D, is a scientific researcher/writer with 37 years of experience in the fields of metabolic and neurological disorders. This includes experience in both academia and the pharmaceutical industry with the majority of time spent at the University of Cambridge and Merck Sharp & Dohme in the United Kingdom. He has also been affiliated with the University of Campinas in Sao Paulo Brazil since 2015, still focused on advancing the field of biomarkers for neurological disorders such as schizophrenia and Alzheimer’s disease, and more recently in the area of anti-aging research.